Direct-to-consumer advertising distorts prescription drugs’ benefits and costs
Common Sense Family Doctor
FEBRUARY 15, 2025
It also does not change the context that most patients overestimate drug safety and that the most heavily advertised drugs have lower added benefit compared with similar medications. The annual price of risankizumab is $288,000, so this is still a huge bargain for the company given the potential returns. If it did, why give it for free?
40 
Let's personalize your content